Agilent Technologies, Inc. (NYSE:A) Receives Average Rating of "Moderate Buy" from Analysts

FierceBiotechGHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm

Clinical OMICsEarly Medical Care Linked to Rapid Gut Microbiome Shifts in Amazonian Indigenous Communities

Clinical OMICsAI Shows Value for Breast Cancer Prediction

FierceBiotechQiagen links with chip giant Nvidia to propel AI use in drug discovery

Clinical OMICsMolecular Imaging Could Detect Early Kidney Fibrosis

Clinical OMICsUltra-Short Radiotherapy Schedule for Prostate Cancer Supported by HERMES Trial

Endpoints NewsI&I biotech cAMPfield attracts top-tier investors in $180M Series A

Clinical OMICsMYC Protein Linked to Tumor Survival Through DNA Repair Pathway

Endpoints NewsThe next big pharma company will come from China

Clinical OMICsctDNA and Immune Signals Reveal Who Benefits Most from Metastasis-Directed Radiation

Endpoints NewsDriven by GLP-1s, pharma’s relationship with consumers is starting to change

Clinical OMICsImpact of Current Genetic Testing on Cancer Survivor Treatment